A Molecular Algorithm Reframes Metastatic PPGL Treatment Choices
Pheochromocytoma and paraganglioma care has long been forced to operate in the space between biology and uncertainty. These tumors are rare, clinically variable, and still treated as having metastatic potential even though three quarters remain localized, because no biochemical marker reliably predicts which lesions will spread.
The practical consequence is stark: clinicians must make systemic treatment decisions without the kind of validated risk tools that guide many other cancers. Camilo Jimenez, MD, and colleagues at the University of Texas MD Anderson Cancer Center have responded with an algorithm that tries to bring order to that uncertainty by combining molecular profile, disease tempo, and treatment availability into a stepwise framework for metastatic pheochromocytoma and paraganglioma.
Their approach, described in the Journal of Clinical Endocrinology & Metabolism and discussed in Endocrine News, does not pretend that one pathway fits every patient. Instead, it starts with tumor biology, then asks how quickly the disease is progressing, and only then moves to therapy selection. That sequencing matters because PPGL is not one disease in the usual sense; it is a family of neuroendocrine tumors with distinct molecular drivers, varying growth rates, and different responses to systemic therapy.
Molecular Subtyping Comes Before Drug Selection
The algorithm divides patients into four groups based on molecular profile, then further classifies them by the rate of progression before assigning first- and second-line options or clinical trial entry. In practice, this reflects an important shift away from treating all advanced PPGL as though cytotoxic chemotherapy were the default answer.
Historically, cyclophosphamide, vincristine, and dacarbazine have been used when tumor shrinkage is needed, but their toxicity profile is substantial. Newer options, including radioligands, tyrosine-kinase inhibitors, and other targeted or systemic therapies, offer a different balance of efficacy and tolerability. The algorithm exists to help clinicians decide when those newer agents should move ahead of older chemotherapy regimens and when the reverse may still be true because of access, urgency, or disease behavior.
For endocrine oncology, the logic is familiar even if the disease is rare. Molecular origin often shapes drug sensitivity, and the same principle now drives treatment thinking in PPGL. Pseudohypoxia-linked tumors, for example, are biologically distinct from other subtypes, and that distinction is especially relevant now that belzutifan has entered the therapeutic conversation as an oral option for selected patients.
A Patient Course That Changed With the Disease
The case embedded in the paper shows why fixed treatment ladders often fail in PPGL.
A 67-year-old man presented in 2020 with progressive fatigue, abdominal pain, hypertension, palpitations, and headaches over several weeks and was diagnosed with paraganglioma syndrome type 4. His primary tumor was large and unresectable because of its highly vascular location, so clinicians selected CVD chemotherapy with the goal of shrinking the tumor enough to allow future resection. That strategy worked well enough for surgery, and he remained disease free for two years.
When the tumor recurred, the biology looked different enough to warrant a new plan. Functional imaging was repeated, the pace of disease had changed, and the illness was no longer considered rapidly progressive even though cure was off the table. Radiopharmaceutical therapy with lutetium-177-DOTATATE was then used to avoid some of the toxicities associated with alternative options, though the patient required intensive care unit admission to receive it.
This is where PPGL management becomes especially difficult. A tumor may behave aggressively at one point in its course and more indolently later, and the treatment strategy has to track that shift rather than remain anchored to the first presentation. Re-imaging and re-phenotyping are not optional embellishments in this setting; they are core parts of the decision-making process.
Belzutifan Changes the Therapeutic Conversation
The arrival of belzutifan has altered how physicians think about systemic therapy in PPGL, particularly for pheochromocytoma characterized by pseudohypoxia. Jimenez described the oral agent as a convenient option that produced sustained improvement in the patient after earlier regimens had failed to provide durable control.
Belzutifan inhibits hypoxia-inducible factor 2α, a pathway tied to pseudohypoxic signaling and tumor survival. Mechanistically, that makes it a rational fit for a subset of PPGLs in which abnormal oxygen-sensing pathways are part of the biology driving the disease. The appeal is not just convenience; it is the alignment between molecular vulnerability and targeted treatment design.
Still, the drug is not a universal solution. It does not cure the disease, and it will not work for every patient. Its role is best understood as another tool in a disease space where durable control often depends on matching treatment to biology, tumor burden, and symptom trajectory.
The sequence in this case also reflected availability. Jimenez made clear that the patient’s path did not perfectly follow the algorithm because each therapy became available at different times, not because the framework itself was flawed. That is a realistic feature of oncology practice, where access, regulatory approval, and disease tempo often intersect in messy ways.
Access Gaps Shape Real-World Use
The algorithm is designed with global use in mind, but global use is not the same as global uniformity. Molecular subtyping is not universally available, and even when it is, costs and infrastructure vary widely. Belzutifan is approved by multiple regulatory agencies, yet approval does not guarantee access in every health system.
That tension runs through the entire framework. In lower-resource settings, chemotherapy may remain the only practical option, not because it is always the best biologic fit, but because it is the therapy that can actually be obtained. The algorithm does not deny that reality; it tries to make room for it while still encouraging clinicians to think beyond automatic defaults.
Jimenez framed the issue plainly: progress in this orphan disease will require stronger data, broader collaboration, and likely multinational efforts to mount adequately powered phase 3 trials. Those studies are hard to assemble, expensive to run, and difficult to fund. The scarcity of patients is itself a scientific barrier, and it leaves expert-driven algorithms filling space where randomized evidence remains thin.
What the Field Still Needs
The paper’s central value lies in its honesty. PPGL treatment is advancing, but it is advancing unevenly, and the field still lacks the level of evidence that would make management straightforward across geographies and tumor subtypes. The algorithm offers structure, not certainty, and it asks clinicians to integrate molecular biology with the realities of access and toxicity.
For now, that may be the most clinically useful approach available. The next unanswered questions are practical ones: which molecular groups benefit most from each systemic strategy, how long responses to belzutifan last in real-world practice, and how to build trials large enough to compare these options head to head in a disease that remains rare by any standard.